# INSTITUTIONAL BIOSAFETY COMMITTEE

UNIVERSITY of WASHINGTON

**Meeting Minutes**

**Date:** Wednesday, October 16, 2019
**Time:** 10:00 AM – 12:00 PM

**Location:** Foege N130A

**Members Present:**
1. Garry Hamilton (*Community Member*)
2. Kevin Hybiske, Allergy and Infectious Diseases
3. David Koelle, Allergy and Infectious Diseases
4. Scott Meschke, Environmental & Occupational Health Sciences
5. Susan Parazzoli (Community Member)
6. Jason Smith, Microbiology (*IBC Vice Chair*)
7. Paul Swenson, Seattle-King Co. Dept. of Public Health (*Community Member*)

Commonly Used Abbreviations
IBC: Institutional Biosafety Committee
BSO: Biological Safety Officer
BUA: Biological Use Authorization
BSL: biosafety level
PI: Principal Investigator
IACUC: Institutional Animal Care and Use Committee
NIH: National Institutes of Health
DURC: Dual Use Research of Concern
SOP: standard operating procedure

1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:00 a.m. A quorum was present.

2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.

3. **APPROVAL OF MINUTES:**
   - The IBC Chair sought a motion to approve the minutes from the September 18, 2019 meeting.
   - A member made a motion to approve the September 18, 2019 minutes. Another member seconded the motion.
   - The committee voted unanimously to approve the September 18, 2019 meeting minutes. There were two abstentions.

4. **OLD BUSINESS:**
   - At the August 2019 meeting, Dr. Zhang's BUA was approved pending a successful lab inspection pending. This is still pending.
   - At the September 2019 meeting, Dr. Akilesh's BUA was approved pending a successful lab inspection. This BUA has been sent out.
   - At the September 2019 meeting, Dr. Horwitz's BUA was approved pending IACUC review, testing HSV for resistance, and occupational health recommendations. This is still pending.
   - At the September 2019 meeting, Dr. Seshadri's BUA was approved pending a successful lab inspection. This BUA has been sent out.
   - At the September 2019 meeting, Dr. Wood's BUA was approved pending a successful lab inspection. This is still pending.

5. **BIOSAFETY OFFICER (BSO) REPORT***:* The Biosafety Officer Report includes (1) projects involving recombinant or synthetic nucleic acids covered under section III-E and III-F of the *NIH Guidelines,* (2) proposals involving non-recombinant biohazardous agents requiring BSL-1 and BSL-2 containment, and (3) administrative updates, such as room additions.

   a. Biosafety Officer Report
      - Dr. King added use of the Pathology Flow Cytometry Core Facility to the BUA *Neil King Lab Biological Use Authorization.*
      - Dr. Dodd renewed a BUA using various BSL2 agents in vitro.
      - Dr. Raftery renewed the BUA *Cell Metabolomics* using human and non-human primate blood, tissue, body fluids, and cell lines in vitro.
      - Dr. Greninger added the use of chimpanzee herpes virus for in vitro work to the BUA *Discovery and Characterization of Virus-Host Interactions.*
      - Dr. Adams Waldorf added a new lab space to the following BUAs: *Experimental Model for Chorioamnionitis and Preterm Labor, Experimental Model of Viral-Induced Brain Injury,* and *Influenza Virus Model of Immunity in Pregnancy.*
      - Dr. Giltiay was approved to take over the BUA *Lymphocyte Activation (Role of CD22 & Syk Kinase)* from D. Clark. This project uses Salmonella Typhimurium, West Nile Virus, and Zika Virus in vitro and in mice.
      - Dr. Samy renewed the BUA *Environmental Health Laboratory* using human blood, tissue, body fluids, and cell lines in vitro.
      - The IBC Chair sought a motion to approve this month's Biosafety Officer Report.

- A member made a motion to approve this month's Biosafety Officer Report. Another member seconded the motion.
- The Committee unanimously voted to approve this month's Biosafety Officer Report. There was one abstention.

6. **DURC REPORT:** The Dual Use Research of Concern Institutional Review Entity (DURC IRE) did not meet this month because there were no applications to review.

7. **NATIONAL BIOSAFETY MONTH PRESENTATION:** A presentation was given by EH&S on the 2019 National Biosafety Month theme: *Beyond the Lab.* NIH has held National Biosafety Month since 2014. This presentation was also given at the Monthly Research Administration Meeting (MRAM) and the University-Wide Health and Safety Committee.

8. **INDIVIDUAL PROJECT REVIEWS**

**a.** Groat Carmona, Anna M., new, *Characterizing the complex protein network that modulates Plasmodium parasite membrane morphogenesis during liver-stage development*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This project works to identify and characterize the complex protein network on the Plasmodium parasite plasma membrane during liver-stage development. It also focuses on characterizing the role of conserved coding-region regulatory RNA elements in the Dengue virus life cycle.
- The greatest biohazard identified is work with the DENV2 virus.
- The biosafety officer will follow up with the lab to receive clarification on student work within this lab.
- The lab was recently inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Groat Carmona.
- The Committee voted unanimously to approve the draft BUA for Dr. Groat Carmona.

**b.** Nair, Sunila, new, *Neurobiology of addiction*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This lab investigates brain mechanisms that underlie drug or food-taking and seeking behaviors and their interaction with stress.
- Work involves use of adeno-associated viral vectors (adenovirus free), canine adenoviral vectors, and replication deficient Herpes simplex viral vectors in rats.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Nair with the following conditions: 1) Approve HSV-1 at BSL-2 with the possibility of lowering containment to BSL-1 if data for RCV testing is provided; 2) Approve CAV and AAV as written conditional on providing a list of transgenes (If oncogenes are listed then this application must go back for full IBC review in November).
- The Committee voted unanimously to approve the draft BUA for Dr. Nair pending the conditions stated above.

**c.** Wakimoto, Barbara T., renewal, *Developmental Genetic Analysis of Fertilization Pathways in Drosophila*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This lab uses a Drosophila model to study molecular mechanisms of sperm development and fertilization.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Wakimoto.
- The Committee voted unanimously to approve the draft BUA for Dr. Wakimoto.

**d.** Waterston, Robert, renewal, *Single Cell Gene Expression in C. elegans*

- The assigned IBC Primary Reviewer presented the Primary Review.
- This projects aims to identify when and where individual transcription factors are expressed during embryonic development of C. elegans. Work involves generating transgenic C. elegans.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Waterston pending corrections to the BUA application.
- The Committee voted unanimously to approve the draft BUA for Dr. Waterston pending corrections to the BUA application.

**e.** Yazdan-Shahmorad, Azadeh, new, *Understanding the underlying mechanisms of neural simulation*

- The IBC Chair presented the Primary Review.
- This lab uses optogenetics to control and measure neural activity in rats to understand neural circuits. The goal is to provide a better understanding of neural plasticity that leads to recover from strokes and may allow for treatment of neurological disorders.
- Work involves use of lentiviral vectors, non-HIV pseudotyped, replication deficient and adeno-associated viral vectors (adenovirus free) in rats.
- The lab was inspected and no deficiencies were identified.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Chair made a motion to approve the draft BUA for Dr. Yazdan-Shahmorad.
- The Committee voted unanimously to approve the draft BUA for Dr. Yazdan-Shahmorad.

**9. SUBCOMMITTEE REPORTS:**

**f.** Green, Damian, new, *A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma*

- Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.

- This is a Car-T clinical trial for therapy for relapsed or refractory myeloma. Transduced patient cells will be infused intravenously into participants at UWMC.
- The possibility of percutaneous exposure to the cell product during thawing or infusion is the greatest biohazardous risk to hospital staff.
- The subcommittee has unanswered questions for the PI and would like to see additional RCL information to perform an adequate risk assessment.
- The draft BUA letter was shown.
- A member made a motion to approve the draft BUA letter for Dr. Green pending PI response to IBC reviewer questions and additional subcommittee review. Another member seconded the motion.
- The Committee voted unanimously to approve the draft BUA for Dr. Green pending PI response to IBC reviewer questions and additional subcommittee review.

**10. FOR YOUR INFORMATION:**

- **NIH Incident Report:** An individual was collecting blood from a non-human primate using a butterfly needle with a vacutainer holder. The individual noticed blood had collected in the vacutainer housing. Before placing the next tube in the vacutainer, the individual attempted to clean some of the blood from the inside of the vacutainer housing. During the process, the person stuck their finger on the needle inside of the housing. The individual was not following standard operating procedures. This incident was reported to the NIH. The NIH OSP stated that the University's response was appropriate, and that no further action was required.
- **SLU 3.1 Biohazardous Waste:** Biohazardous and radioactive material waste was inappropriately collected from floors 5-7 at SLU 3.1 and mixed with general waste. Contractors have cleaned all three floors and the compactor and area. Radiation sampling was completed and all found to be negative. Occupational Health has consulted with labs about potential hazards. Access concerns have been addressed. A contractor will be handling removal of the compacted waste.

**11. ISSUES FROM THE FLOOR & PUBLIC COMMENTS:** There were no issues from the floor, and no public comments.

**12. MEETING ADJOURNED AT APPROXIMATELY 10:59 A.M.**